NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: SAIPARENT · data 2026-11-01
Sai Parenterals Limited
In plain words
Price: 26.1% below its 52-week high of ₹706.
Delivery: 54.0% of traded shares were kept for delivery over the last 10 sessions, against 55.1% over the last 60.
Latest results: a net profit of ₹11 cr for the quarter ended Sept 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | — |
| Net profit (last 12 months) | — |
| Sales growth, 3 years (yearly) | 57.9% |
| Profit growth, 3 years (yearly) | 48.3% |
At a glance
Promoters 51.2%, pledged 0.0%, institutions 10.7%.
ROE 4.9%, ROCE 5.8%: how much profit it earns on the money it uses.
Debt/equity 0.96, Profit growth 48.3% and sales growth 57.9% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Profit grew 48.3% a year over 3 years.
- Low return on equity (4.9%).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
SAIPARENT Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹194.92 crore, up 9.1% QoQ.
Net profit was ₹10.51 crore, up 32.7% QoQ.
Operating margin was 20.6%.
EPS was ₹2.38, up 33% QoQ.
SAIPARENT के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹194.92 करोड़; पिछली तिमाही की तुलना में 9.1% की बढ़त।
शुद्ध मुनाफ़ा: ₹10.51 करोड़; पिछली तिमाही की तुलना में 32.7% की बढ़त।
ऑपरेटिंग मार्जिन: 20.6%।
EPS: ₹2.38; पिछली तिमाही की तुलना में 33% की बढ़त।
SAIPARENTના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹194.92 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 9.1% વધારો.
ચોખ્ખો નફો: ₹10.51 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 32.7% વધારો.
ઓપરેટિંગ માર્જિન: 20.6%.
EPS: ₹2.38; ગયા ક્વાર્ટરની સરખામણીએ 33% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
21/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 14/30: Delivery 53.9% over the last 20 sessions vs 47.7% in the 40 before (1.13x); shares delivered per day 1.44x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 2/15: Verdict "None", sustained score 59/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results
- 1 Nov 26Results Q2 FY27 results: net profit ₹10.5 cr
- 11 Aug 26Results Q1 FY27 results: net profit ₹7.9 cr -6.0% next session
- 23 May 26Results Q4 FY26 results: net profit ₹13.2 cr +0.6% next session
- 23 May 26Results Q3 FY26 results: net profit −₹6.7 cr +0.6% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹195 cr | ₹11 cr | — | 20.6% | 2.38 |
| Jun 2026 | ₹179 cr | ₹8 cr | — | 13.2% | 1.79 |
| Mar 2026 | ₹198 cr | ₹13 cr | — | 13.2% | 4.02 |
| Dec 2025 | ₹96 cr | ₹-7 cr | — | -3.7% | -2.22 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 |
|---|---|---|---|
| Promoters | 51.16% | 51.16% | 51.16% |
| Foreign institutions (FII) | 2.85% | 4.03% | 5.73% |
| Domestic institutions (DII) | 7.84% | 8.53% | 12.86% |
| Mutual funds | 0.30% | 0.98% | 3.81% |
| Retail investors | 9.56% | 6.79% | 4.32% |
| Number of shareholders | 13,645 | 9,312 | 7,687 |
Common questions
What was Sai Parenterals Limited's latest quarterly profit?
Sai Parenterals Limited reported a net profit of ₹11 cr for the quarter ended Sept 2026, on revenue of ₹195 cr.
How much do promoters hold in Sai Parenterals Limited?
Promoters held 51.16% of Sai Parenterals Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Sai Parenterals Limited debt-free?
Its latest reported debt-to-equity ratio is 0.96.
What is the 52-week high and low of Sai Parenterals Limited?
The 52-week high is ₹706 and the 52-week low is ₹400.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Sai Parenterals Limited | ₹521.95 | ₹2,302 cr | — | — | 4.9% | 5.8% | 0.96 | +30.5% |
| Hikal Limited | ₹211.58 | ₹2,601 cr | — | — | -4% | 3.1% | 0.57 | -13.1% |
| Dishman Carbogen Amcis Ltd. | ₹145.02 | ₹2,276 cr | 33.3 | — | 1.6% | 2.6% | 0.46 | -50.5% |
| Fredun Pharmaceuticals Ltd. | ₹1,367 | ₹2,259 cr | 49.7 | — | 15.6% | 33% | 0.87 | -11.2% |
| Alembic Limited | ₹87.22 | ₹2,239 cr | 7 | — | 13.3% | 3.3% | 0 | -13.2% |
| Sakar Healthcare Ltd | ₹944.8 | ₹2,074 cr | 49 | 6.1 | 10% | 12.4% | 0.17 | +167.0% |
Compare SAIPARENT with HIKAL in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SAIPARENT in NSE Scanner →